ALIMERA SCIENCES INC
DelistedCIK 1267602fmd_05ZM55S1AEZDY9ZWF9JQJC30Q7Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Jun 30, 2024, 58 periods
| Line item | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 8 | 22 | 34 | 36 | 47 | 54 | 51 | 59 | 54 | 81 |
| Cost of revenue | 1 | 2 | 2 | 3 | – | – | – | – | – | – |
| Gross profit | 7 | 21 | 32 | 32 | 42 | 47 | 44 | 52 | 46 | 70 |
| Research and development | 12 | 15 | 12 | 13 | 11 | 11 | 10 | 14 | 16 | 17 |
| Selling, general and administrative | – | – | – | – | – | 39 | 32 | 36 | 39 | 46 |
| Total operating expenses | 40 | 60 | 60 | 49 | 52 | 53 | 44 | 52 | 58 | 72 |
| Operating income | (33) | (39) | (28) | (16) | (10) | (5) | (1) | (0) | (12) | (2) |
| Interest expense | 2 | 5 | 5 | 6 | 5 | 5 | 5 | 5 | 6 | 10 |
| Interest and investment income | – | – | – | – | – | – | – | – | – | – |
| Income before taxes | (36) | (31) | (33) | (22) | (16) | (10) | (5) | (4) | (18) | (20) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | (0) | 0 | 0 | 0 |
| Net income from continuing operations | (36) | (31) | (33) | (22) | (16) | (10) | (5) | (4) | (18) | (20) |
| Net income | (36) | (31) | (33) | (22) | (16) | (10) | (5) | (4) | (18) | (20) |
| Net income to common shareholders | (37) | (31) | – | (22) | 22 | (10) | – | – | (18) | (21) |